As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Multiple sclerosis and COVID-19: promising results from AB Science

AB Science is a French biotech headed by Alain Moussy with its scientific committee presided by French Academy of Sciences Member Olivier Hermine. Since this summer, the company has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis
AB Science L. Gros AB Science L. Gros

AB Science saw the day in 2001 and now employs more than 100 people at its headquarters in Paris and its R&D sites in Évry-Courcouronnes (Genopole), Magny-les-Hameaux, Marseille and Lyon. The company was publicly listed on Euronext in 2010 (€586 M).

The French biotech is headed by Alain Moussy and its scientific committee presided by French Academy of Sciences Member Olivier Hermine. Since this summer, the company has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis. More announcements are to come, notably in the setting of Alzheimer’s disease.

Interview with Laurent Gros

Laurent Gros heads AB Science’s drug discovery program at Genopole. We spoke with him about the highly advanced clinical development of masitinib.

You’ve recently announced extremely promising results for the treatment of the two progressive forms of multiple sclerosis…

Laurent Gros: « No other therapeutic product anywhere in the world has ever provided such results in the two progressive forms of multiple sclerosis (MS). Current treatments concern only 50% of patients, those who have relapsing forms of the disease (see inset below) that respond to modulation of the adaptive immune system. Masitinib, a tyrosine kinase inhibitor currently in phase III trials, is aimed at disease forms that respond to modulation of the innate immune system. In our trial involving 656 patients, we have clinically demonstrated that targeting the innate immune system is effective for slowing progressive forms of MS. Our results were announced a few days ago at the joint ACTRIMS-ECTRIMS meeting. »

Does that mean that we can hope to see a cure for these forms of MS thanks to masitinib?

Laurent Gros: « Thinking that orally-administered masitinib will cure this serious and complex disease is illusory, but already, if it can slow its progression, the benefit for patients will be enormous.  They would benefit from a vastly improved quality of life with less relapses, slowed decline and delayed—even possibly no need for—recourse to a wheelchair. Also, our results show that masitinib is not immunosuppressive and that it causes few adverse effects. It may thus be used as a long-term treatment, an important aspect for patients. We will launch a confirmatory phase III study in 2021. Once patients are recruited, at least three years of clinical study will be necessary. ».

Recent results have indicated an antiviral activity of masitinib against SARS-CoV-2. Could you tell us more about that?

Laurent Gros: « With the urgency of the COVID-19 pandemic, current treatment research strategies are largely based on the repurposing of existing therapeutics. Researchers from the University of Chicago recently screened 1900 known molecules. Masitinib was shown to be the best inhibitor of SARS-CoV-2’s principal protease, which is necessary for its replication (article: Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro). Those results were obtained through in vitro modeling and thus in vivo proof of concept will be the next step. The American researchers contacted us to optimize their protocol. We’ve laid the foundation for a potential partnership concerning an antiviral indication for masitinib against COVID-19. The American team is targeting patients in early disease whereas we are in a phase II clinical trial exploring the anti-inflammatory action of masitinib in cases of severe disease caused by a potentially fatal overreaction of the immune system.».

What other paths are being explored?

Laurent Gros: « The research done in American universities also suggest that masitinib is active against other coronaviruses and picornaviruses, which opens a large vista of potential antiviral applications. At an international conference held in early September, we also presented promising results from a phase III trial performed in hundreds of patients with severe asthma. We are furthermore in a phase III trial in Alzheimer’s disease, where mast cell-mediated inflammation appears to play an important role. The objective of that trial is to confirm phase II results suggesting that masitinib’s action on that component has a positive effect on disease course. ».

What is your business model?

Laurent Gros: «Our objective is to pursue our research independently. We keep all rights, which lets us maintain our flexibility, reactivity and creativity. Growth is good, but it needs to occur in a reasonable way.».


    More than 100,000 people in France are afflicted by multiple sclerosis (MS), an autoimmune disease that affects the central nervous system. MS involves a progressive degradation of nerve cells by the patient’s own immune system. It exists in two forms:
    – relapsing-remitting MS (RRMS), characterized by relapses (or “attacks”) of the pathology, followed by remissions;
    – progressive MS, characterized by constant diseases exacerbation with serious, invalidating and irreversible handicapping, much worse than that observed in RRMS.

    Progressive MS is classified as primary or secondary (to RRMS), with further characterization as active or not active.  Progressive MS affects 500,000 people across the globe.

Article posted on 24 September 2020


The latest news

Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

Logos Istem & Généthon

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.

IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

Christophe Lanneau - Research & Platforms Department Director

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.

CNRGH - Consequences of phthalate exposure during pregnancy

Consequences of phthalate exposure during pregnancy

Jörg Tost and his team of the National Center of Human Genomics Research (CNRGH; CEA) were part of a large collaborative study aimed at determining the genome-wide correlation between phthalate exposure during pregnancy and methylation of placental DNA.

INtegrare / Généthon - Efficacité à long terme de la thérapie génique d’un déficit immunitaire

Long-term efficacy for an immunodeficiency gene therapy

A gene therapy conceived by Genethon has been shown to confer long-term efficacy against Wiskott-Aldrich syndrome, an immune deficiency disorder.

I-Stem, IPSEN & LMN recreate the human muscle-nerve system

A cellular model to recreate the human muscle-nerve system

Researchers from I-Stem, IPSEN and LMN have conceived a cellular muscle-nerve model to test the therapeutic potential of botulinum toxins in vitro.

Genoscope - CNS - Genopole's laboratory

Filling the gaps in the banana’s genome

Des chercheurs de Genoscope en collaboration avec une équipe du Cirad sont parvenus à reconstituer la séquence intégrale de chromosomes de bananier.

traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.


Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

muscle fiber

Signs of myopathy detected before muscle formation

An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself

Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

View all >
With the support from
Région île de France